

***A CLINICAL STUDY OF INHALANT ANAESTHESIA
IN DOGS***

Robert George Pottie
BVSc

University Veterinary Centre, Camden
University of Sydney
Camden, NSW, 2570
AUSTRALIA

A thesis submitted for the degree of
Master of Veterinary Clinical Studies

October, 2004

*Apart from the assistance which is acknowledged herein,
this thesis represents the original work of the author.*

*Robert G. Pottie
BVSc*

Acknowledgements

Completion of this study and thesis has been quite a journey. A journey I could not have completed without generous assistance from many quarters.

Thanks must firstly go to Christina Dart, for her enthusiastic supervision along each step of the way. I was very fortunate to have a supervisor who was so accessible and encouraging. Likewise, thanks must go to David Hodgson, for his wisdom and experience in shaping the project.

Nigel Perkins' assistance with statistical analysis was enormous both in quality and quantity. Nick Malikides and Felicity Cole must also take credit in my new-found respect for this "black art".

Many of the final year veterinary students of 2002 gave great assistance in data recording and handling of the animals. The assistance of Jo Rainger, Tabitha Shayler and Ryan Ong was instrumental.

Abbott Animal Health generously supported this study, including supply of the propofol and sevoflurane used.

To my wife Alex and son Stuart.

Summary

A clinical trial was undertaken using three different inhalant anaesthetic agents and one intravenous anaesthetic agent in dogs undergoing routine desexing surgery.

Healthy adult dogs undergoing either ovariohysterectomy or castration were assessed as to their demeanour, with the more excitable dogs being placed in groups receiving premedication with acepromazine and morphine. All dogs were then randomly assigned an anaesthetic agent for induction of general anaesthesia. The agents were the inhalants halothane, isoflurane and sevoflurane, and the intravenous agent propofol. Inhalant inductions were undertaken using a tight fitting mask attached to a standard anaesthetic machine with a rebreathing circuit, with the maximum dose of inhalant available from a standard vaporiser. Propofol inductions were undertaken via intravenous catheter. Dogs induced with propofol were randomly assigned one of the three inhalant agents for maintenance. Those induced by inhalant agent were maintained using the same agent. The surgical procedure was undertaken in standard fashion, as was recovery from anaesthesia. All dogs received the non-steroidal anti-inflammatory agent meloxicam.

Data collection was divided into three stages: induction, maintenance, and recovery from anaesthesia. Variables measured at induction of anaesthesia were time to intubation, number of intubation attempts, tolerance of mask, quality of induction and quality of transfer to the maintenance stage. Standard variables for monitoring of anaesthesia were recorded throughout the maintenance of anaesthesia. Variables measured at recovery were time to righting, time to standing and quality of recovery.

The mean time to intubation when using the newer inhalant sevoflurane (196.2 ± 14.8 sec, mean \pm SE) was not significantly different to that for halothane (221.4 ± 14.0 sec) or isoflurane (172.4 ± 15.0 sec). Time to intubation with isoflurane was significantly faster than with halothane. Mean time to intubation with propofol (85.4 ± 7.7 sec) was significantly faster than that for any of the three inhalants. Choice of inhalant had no effect on quality of induction. The use of premedication significantly improved the quality of induction. The use of propofol for induction likewise significantly improved the quality of induction.

Standard cardiorespiratory variables measured during the maintenance phase of anaesthesia remained within normal clinical ranges for all three inhalants, and were therefore not further analysed.

Choice of inhalant agent had no significant effect on the time to righting or standing in recovery. The use of propofol for induction had no effect on these variables. Animals placed in groups receiving premedication had significantly longer times to righting and standing. The oesophageal temperature at the end of the procedure had a significant effect on times to righting and standing, with lower temperatures contributing to slower recoveries. Independent of procedure time, male dogs had shorter times to righting than female dogs.

Table of Contents

<i>A CLINICAL STUDY OF INHALANT ANAESTHESIA IN DOGS</i>	i
Summary	iv
Table of Contents	vi
List of Tables	x
List of Figures	xi
List of Abbreviations	xii
Introduction	1
Chapter 1: Literature Review	5
1.1 Inhalant anaesthetics	6
1.1.1 History.....	6
1.1.2 Chemical composition	6
1.1.3 Method of action	7
1.1.4 Therapeutic effects.....	8
1.1.4.1 Dose requirements	8
1.1.4.2 Factors affecting induction of anaesthesia.....	9
1.1.4.3 Recovery from anaesthesia	12
1.1.5 Side effect profile.....	12
1.1.5.1 Effects on cerebral function.....	12
1.1.5.2 Effects on the cardiovascular system.....	13
1.1.5.2.1 Effects on heart rate	13
1.1.5.2.2 Effects on cardiac rhythm	14
1.1.5.2.3 Effects on cardiac contractility	14
1.1.5.2.4 Effects on diastolic function	15
1.1.5.2.5 Effects on vasculature	15
1.1.5.2.5.1 Systemic vasculature.....	15
1.1.5.2.5.2 Coronary vasculature	15
1.1.5.2.5.3 Cerebral vasculature.....	16
1.1.5.2.6 Effects on blood pressure.....	16
1.1.5.3 Effects on the Respiratory System.....	16
1.1.5.3.1 Odour and Irritancy	16
1.1.5.3.2 Respiratory effects post-induction	17
1.1.5.4 Effects on renal function.....	18
1.1.5.5 Effects on the liver	19
1.1.6 Hazards of occupational exposure	20
1.1.7 Environmental effects	20
1.2 Propofol.....	22
1.2.1 Composition.....	22
1.2.2 Pharmacokinetics	22
1.2.3 Metabolism	23
1.2.4 Induction of and recovery from anaesthesia	23
1.2.5 Side effects profile	24
1.2.5.1 Cardiovascular effects.....	24
1.2.5.2 Respiratory effects	24
1.2.5.3 Proconvulsant/anticonvulsant effects.....	25
1.3 Acepromazine	26
1.3.1 Introduction.....	26
1.3.2 Method of action	26

1.3.3 Therapeutic effects.....	26
1.3.4 Side effects profile	27
1.4 Morphine.....	29
1.4.1 History and derivation.....	29
1.4.2 Pharmacology	29
1.4.3 Therapeutic effects.....	30
1.4.4 Side effects profile	30
1.5 Meloxicam	32
1.6 Conclusion	34
Chapter 2: Materials and Methods	36
2.1 Study Objectives	37
2.2 Experimental design.....	37
2.3 Anaesthesia protocols	39
2.3.1 Premedication	39
2.3.2 Intravenous catheterisation	39
2.3.3 Induction protocols	40
2.3.3.1 Inhalant agent inductions	40
2.3.3.2 Intravenous agent inductions	44
2.3.4 Maintenance of anaesthesia	46
2.3.5 Recovery	47
2.3.5.1 Supplementary analgesia	48
2.4 Surgery	48
2.5 Data Collection	49
2.5.1 Prior to anaesthesia	49
2.5.1.1 Quantitative data	49
2.5.1.1.1 General health status	49
2.5.1.2 Qualitative data	49
2.5.1.2.1 Demeanour.....	49
2.5.1.2.2 Sedation.....	50
2.5.2 During induction of general anaesthesia.....	50
2.5.2.1 Quantitative data	50
2.5.2.1.2 Time to intubation.....	51
2.5.2.1.3 Intubation attempts.....	51
2.5.2.1.4 Dose of propofol prior to intubation	52
2.5.2.1.5 Dose of propofol post-intubation	52
2.5.2.2 Qualitative data	52
2.5.2.2.1 Tolerance of mask.....	52
2.5.2.2.2 Quality of induction	53
2.5.2.2.3 Quality of transfer	53
2.5.3 During maintenance of anaesthesia	54
2.5.3.1 Quantitative data	54
2.5.3.1.1 Cardiovascular variables	54
2.5.3.1.2 Respiratory variables.....	55
2.5.3.1.3 Temperature	56
2.5.3.1.4 Frequency of data collection	56
2.5.3.1.5 Other quantitative data	56
2.5.3.2 Qualitative data	57
2.5.4 Recovery from anaesthesia	57
2.5.4.1 Quantitative data	57
2.5.4.1.1 Time of extubation.....	57

2.5.4.1.2 Time to righting	57
2.5.4.1.3 Time to standing	57
2.5.4.2 Qualitative data	57
2.5.4.2.1 Quality of recovery	57
2.6 Statistical Analysis	58
2.6.1 Time to intubation.....	58
2.6.2 Quality of induction	59
2.6.3 Propofol dose for induction	59
2.6.4 Time to righting	59
2.6.5 Time to standing	59
2.7 Costing of agents.....	59
Chapter 3: Results.....	61
3.1 Cases enrolled	62
3.2 Group allocation.....	62
3.3 Prior to induction of anaesthesia.....	63
3.4 Induction of anaesthesia.....	63
3.4.1 Inhalant inductions.....	63
3.4.2 Intravenous inductions	64
3.4.2.1 Propofol dose requirements	64
3.4.3 Intubation attempts.....	64
3.4.4 Time to intubation.....	65
3.4.5 Quality of induction	67
3.5 Intraoperative Variables.....	67
3.6 Recovery from anaesthesia	76
3.6.1 Time to righting	76
3.6.2 Time to standing	76
3.7 Cost of induction and maintenance of anaesthesia	77
Chapter 4: Discussion	79
4.1 Introduction.....	80
4.2 Experimental design.....	80
4.3 The clinical environment	81
4.4 Induction of anaesthesia.....	83
4.4.1 Time to induction.....	83
4.4.1.1 Introduction.....	83
4.4.1.2 Definition	83
4.4.1.3 Experimental group size	84
4.4.1.4 Intravenous inductions	84
4.4.1.5 Halothane dosage	84
4.4.1.6 Failed inhalant inductions	85
4.4.1.7 Effect of premedication.....	86
4.4.1.8 Clinical significance.....	87
4.4.2 Quality of induction	88
4.4.2.1 Measuring quality	88
4.4.2.2 Effect of premedication.....	89
4.4.2.3 Intravenous inductions	89
4.5 Recovery	89
4.5.1 Introduction.....	89
4.5.2 Time to righting and standing.....	90
4.5.2.1 Duration of anaesthesia.....	90
4.5.2.2 Choice of induction agent	90

4.5.2.3 Effect of premedication.....	91
4.5.2.4 Effect of body temperature	91
4.6 Intra-anaesthesia variables	92
4.6.1 Biological significance.....	92
4.6.2 Heart rate.....	93
4.6.3 End-tidal carbon dioxide concentration	93
4.6.4 Mean arterial blood pressure.....	94
4.6.5 End-tidal inhalant anaesthetic agent concentration.....	95
4.7 Financial considerations.....	96
4.8 Conclusion	97
Chapter 5: References	99

List of Tables

		Page
Table 1.1	Selected, relevant chemical data for halothane, isoflurane and sevoflurane	7
Table 1.2	Canine dose requirements for inhalant anaesthetics	9
Table 2.1	Experimental groups	38
Table 3.1	Experimental group allocation	62
Table 3.2	Time to intubation	66
Table 3.3	Quality of induction scores	67
Table 3.4	Intraanaesthesia variables	69

List of Figures

		Page
Figure 3.1	Time to intubation, in minutes	66
Figure 3.2	Heart rate in dogs anaesthetised using halothane, isoflurane and sevoflurane, with and without premedication	70
Figure 3.3	Mean arterial pressure in dogs anaesthetised using halothane, isoflurane and sevoflurane, with and without premedication	71
Figure 3.4	Mean end-tidal carbon dioxide concentrations in dogs anaesthetised using halothane, isoflurane and sevoflurane, with and without premedication	72
Figure 3.5	Mean end-tidal inhalant anaesthetic concentrations (vol%) in dogs anaesthetised using halothane, isoflurane and sevoflurane, with and without premedication	73
Figure 3.6	Mean end-tidal inhalant anaesthetic concentrations (MAC multiples) in dogs anaesthetised using halothane, isoflurane and sevoflurane, with and without premedication	74
Figure 3.7	Oesophageal temperature at end procedure and its effect on recovery, in terms of time to righting	75
Figure 3.8	Effect of premedication on recovery from anaesthesia	77

List of Abbreviations

ACP	Acepromazine
ANOVA	Analysis of variance
A\$	Australian dollars
Br	Bromine
BP	Barometric pressure
CBF	Cerebral blood flow
°C	Degrees Celsius
CaEDTA	Calcium ethylene diaminetetraacetic acid
CDC	Canine Desexing Clinic
CI	Confidence interval
Cl	Chlorine
cmH ₂ O	Centimetres of water
CMRO ₂	Cerebral metabolic requirement for oxygen
CNS	Central nervous system
CO ₂	Carbon dioxide
COX-1	Cyclo-oxygenase isoform 1
COX-2	Cyclo-oxygenase isoform 2
dP/dt	Rate of change of pressure over time
drops.ml ⁻¹	Drops per millilitre
ED ₉₅	Estimated dose (95%)
EDTA	Ethylene diaminetetraacetic acid
ECG	Electrocardiogram
EEG	Electroencephalogram
ETA	End-tidal inhalant anaesthetic concentration
F	Fluorine
G	Gauge
GST	Goods and services tax
GWP	Greenhouse Warming Potential
Hal	Halothane
hr	Hour

ICP	Intracranial pressure
Iso	Isoflurane
IU.ml ⁻¹	International units per millilitre
IM	Intramuscular
kg	Kilogram
l.min ⁻¹	Litres per minute
m	Metre
MAC	Minimum alveolar concentration
MAP	Mean arterial pressure
mg.kg ⁻¹	Milligrams per kilogram
ml.kg.min ⁻¹	Millilitres per kilogram per minute
mg.ml ⁻¹	Milligrams per millilitre
min	Minute
mmHg	Millimetres of mercury
ml.min ⁻¹	Millilitres per minute
ml.sec ⁻¹	Millilitres per second
ng.ml ⁻¹	Nanograms per millilitre
NSAID	Non-steroidal anti-inflammatory drug
O ₂	Oxygen
ODP	Ozone Depletion Potential
OR	Odds ratio
P _A	Alveolar partial pressure
P _V	Venous partial pressure
Pro	Propofol
Q	Cardiac output
SC	Subcutaneous
SD	Standard deviation
SE	Standard error
sec	Second
Sevo	Sevoflurane
SpO ₂	Haemoglobin oxygen saturation
µg.ml ⁻¹	Micrograms per millilitre
λ	Blood:gas solubility

Introduction

Inhalation was the only means of delivery of agents for general anaesthesia for almost one hundred years. Whilst indications for the use of intravenous anaesthetics have developed in more recent years, inhalant agents remain widely used in human and veterinary anaesthesia (Steffey 1996). The value of inhalants lies in their flexibility and predictability; primarily for maintenance of anaesthesia, but also for induction.

The development of halothane in the early 1950's represented a significant progression in inhalant anaesthesia. Its fluorinated alkane structure produced a volatile liquid that was non-flammable, and considerably less toxic to the patient than older agents such as diethyl ether (Steffey 1996; Fee and Thompson 1997). However, its side effect profile, and specifically its ability to occasionally produce a fatal acute hepatitis in the human, encouraged the pursuit of superior agents. Isoflurane and sevoflurane were products of this search. Isoflurane, introduced into commercial use in the 1970's, was significantly less soluble in blood than halothane, and was free of the hepatic side effects. It possessed, unfortunately, a notably more irritating smell than halothane. Sevoflurane, although first synthesised in the 1970's, was not released in the US until 1995. It is even less soluble in blood than isoflurane, and has a less irritating odour (Brown 1995; Sinha *et al.* 1996).

Little is known about the method of action of inhalant anaesthetics. It appears likely that immobility is mediated through the action of the agent on the motor interneurons of the spinal cord (Rampil and King 1996), as removal of the entire cerebrum and brainstem does not reduce the inhalant anaesthetic dose requirement to prevent movement in response to stimulus (Rampil *et al.* 1993). It is suggested that the inability to recall events under anaesthesia may be due to effects of the inhalant on higher centres of the brain (Koblin 1994; Eger *et al.* 2002).

Induction of anaesthesia with inhalant agents is dependent upon the interplay of several factors. Increasing cardiac output, minute respiratory volume or the gradient between the alveolar concentration and arterial concentration will increase the speed of induction. Whilst manipulation of cardiac output may be infeasible at the point of induction of anaesthesia, minute respiratory volume may be influenced by the method of inhalant induction and the smell of the inhalant, and the slope of the

concentration gradient is influenced by the inhalant vaporiser settings and gas flow rates used (Eger 1974). A small number of studies have compared the speed and quality of induction of anaesthesia using the modern inhalant agents in the dog. Equipotent doses of 2.0.MAC of isoflurane and sevoflurane delivered a significantly more rapid time to intubation for sevoflurane than isoflurane (Johnson *et al.* 1998). Doses of 2.5.MAC produced similar results, with sevoflurane significantly faster to intubation than isoflurane, which in turn was significantly faster than halothane (Mutoh *et al.* 1995). However, standard practice in many veterinary practices is to use the maximum dose of the inhalant available from a standard vaporiser, which is in excess of 3.0.MAC, particularly for halothane. A previous study examined induction of anaesthesia using halothane and isoflurane at close to maximum vaporiser output, revealing no significant differences in induction speed (Hellebrekers 1986). Recovery from anaesthesia is reliant on the same factors as induction. Dogs anaesthetised with halothane recovered to standing slower than those anaesthetised with isoflurane in an experimental study (Hellebrekers 1986). A similar study of recovery from anaesthesia using isoflurane or sevoflurane could elucidate no differences between the two agents (Johnson *et al.* 1998).

Whilst the newer inhalants have overcome the acute hepatitis occasionally associated with halothane, all three agents do have effects on several body systems which are not beneficial. There are case reports in the human literature of seizure activity associated with sevoflurane anaesthesia (Adachi *et al.* 1992; Terasako and Ishii 1996; Woodforth *et al.* 1997; Kaisti *et al.* 1999; Iijima *et al.* 2000), although similar problems have not been revealed in the dog (Scheller *et al.* 1990). Halothane anaesthesia causes a greater increase in ICP and CBF than that occurring with the two newer inhalants, which may retain these values within normal limits (Scheller *et al.* 1990; Kuroda *et al.* 1997; Monkhoff *et al.* 2001).

All three inhalants have important effects on the cardiovascular system. Halothane's ability to sensitise the heart to catecholamine-induced arrhythmias was a strong motivation for further development of the fluorinated alkane inhalant anaesthetics (Wallin *et al.* 1975; Steffey 1995). The adrenaline concentrations required to cause cardiac arrhythmias in the dog are far higher with isoflurane and sevoflurane than with halothane. All three agents decrease cardiac output (Steffey and Howland 1978; Bernard *et al.* 1992; Mutoh *et al.* 1997), halothane being somewhat more depressive of CO than isoflurane or sevoflurane. The three inhalants are

significant vasodilators (Malan *et al.* 1995; Holzman *et al.* 1996). Although greater vasodilation with the two newer inhalants leads to slightly lower MAP values than with halothane, statistically significant differences have not been demonstrated in several studies (Bernard *et al.* 1990; Frink *et al.* 1992a; Harkin *et al.* 1994; Malan *et al.* 1995; Mutoh *et al.* 1995).

Of the three agents, isoflurane is the most irritant to the respiratory tract, followed by halothane, with sevoflurane being the most benign (Doi and Ikeda 1993). This may well impact on the relative suitability of the three agents for induction of anaesthesia. All three cause depression of ventilation in the anaesthetised patient, isoflurane and sevoflurane both causing greater depression than halothane (Mutoh *et al.* 1995; Mutoh *et al.* 1997).

The development of sevoflurane was delayed by concerns that fluoride ions, produced by metabolism of the agent, and a polyvinyl ether, arising from interaction of the agent with carbon dioxide absorbents, would be deleterious to renal function in the patient (Brown 1995). Whilst this appeared to be an issue in rats, no strong evidence of kidney dysfunction has been found in humans following sevoflurane anaesthesia (Patel and Goa 1996). None of the three agents produce changes in renal blood flow (Gelman *et al.* 1984; Crawford *et al.* 1992). However, blood flow to the liver is reduced, although this is not thought to be of consequence in the absence of other complicating factors (Steffey 1995).

The objectives of the current study were to investigate the speed and quality of anaesthetic induction and recovery using the three inhalants. This was to be carried out in the clinical domain. Whilst previous research in the human field has thoroughly compared the inhalants in the clinical domain, as summarised by Patel and Goa (1996), the veterinary literature is restricted almost entirely to the experimental situation; clinical veterinary studies have only been of a qualitative or non-comparative nature (Mutoh *et al.* 1995; Johnson *et al.* 1998; Tzannes *et al.* 2000; Haitjema and Cullen 2001).

Inhalant agents are not the most common agents used for induction of anaesthesia in private veterinary practice, with the use of intravenous anaesthetic agents more popular (Nicholson and Watson 2001). Propofol is a relatively new intravenous agent, having been first synthesised in the 1970s (Reves *et al.* 1994). It is attractive due to the generally high quality of the induction associated with its use (Weaver and Raptopoulos 1990; Zoran *et al.* 1993), and its ability to be metabolised

outside of the liver (Veroli *et al.* 1992). Induction is rapid, and recovery from a single induction bolus is adjudged complete within approximately 20min (Watkins *et al.* 1987). A reduction in cardiac output of approximately 20% occurs during induction with propofol (Brussel *et al.* 1989), persisting for less than 5min. A period of apnoea lasting approximately 30sec is often associated with induction (Watkins *et al.* 1987; Morgan and Legge 1989; Zoran *et al.* 1993), although the related rise in arterial CO₂ is mild in biological terms (Robertson *et al.* 1992). Paradoxically, propofol is noted to have both proconvulsant and anticonvulsant properties, with trembling and tonic-clonic type activity often noted at induction (Weaver and Raptopoulos 1990; Robertson *et al.* 1992). No published studies have compared the induction of anaesthesia with propofol to that of inhalant agents in the veterinary clinical situation.

Premedication is commonly used in veterinary practice to decrease the dose of induction agent required, to provide analgesia and to increase the quality of induction and maintenance of anaesthesia (Thurmon *et al.* 1996). Acepromazine and morphine provides a suitable neuroleptanalgesic combination for these purposes (Thurmon *et al.* 1996). For those animals undergoing invasive surgery without the benefit of such premedication, some form of postoperative analgesia is important. This may be provided by perioperative use of a non-steroidal anti-inflammatory drug such as meloxicam.